Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence Gaps and Patient Access
Healthcare stakeholders were informed in the Netherlands that Chronic Pain Rehabilitation through Interdisciplinary Medical Specialist Rehabilitation (IMSR) will be removed from the Dutch basic health insurance package for most patients. Under the new ruling by Zorginstituut Nederland, chronic pain rehabilitation will remain conditionally reimbursed until 2030 exclusively for those in whom all first-line treatments have failed.
Retracted Studies Trigger Policy Shift
The Dutch National Health Care Institute has directly linked the retraction of two foundational studies in 2024 to its decision to restrict reimbursement. Although these studies had previously supported IMSR effectiveness, their withdrawal left the overall evidence base insufficient. The Institute will reassess the program in 2030 based on new research generated by the professional community.
IMSR is a specialized, outpatient multidisciplinary program that addresses the physical, psychological, and social aspects of complex chronic pain through a single integrated treatment plan. According to the Institute, the majority of the 23,500 patients currently referred annually can be managed effectively with less intensive first-line care from general practitioners, physiotherapists, or psychologists. Only the smallest subgroup with truly refractory pain will continue to qualify for conditional reimbursement.
Safeguards Ensure Appropriate Utilization
To prevent overuse, Zorginstituut Nederland has worked with rehabilitation physicians, patient organizations, and insurers to create a strict indication tool. This document verifies that every appropriate first-line treatment has been tried and has failed before IMSR can be approved. Patients already in treatment or formally indicated will not experience abrupt discontinuation, protecting care continuity during the transition.
A formal implementation plan launching in May 2026 will strengthen coordinated first-line multidisciplinary care and improve understanding of which patients benefit from which interventions. This forms part of the broader Dutch “appropriate care” initiative aimed at delivering the right care at the right time while making responsible use of limited rehabilitation resources.
Lessons for Evidence-Based Reimbursement
This decision highlights the vulnerability of reimbursement when it rests on retracted or limited evidence. It highlights the increasing demand for high-quality randomized trials and real-world evidence, even for non-pharmacological multidisciplinary programs. The Dutch managed-entry approach—conditional coverage until 2030 explicitly tied to new research—offers a pragmatic model for balancing patient access with the need for robust evidence.
